These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 10796397)

  • 1. Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al.
    Yin H; Liu B; Li Q; Yan Q; Lu L
    Arthritis Rheumatol; 2023 Mar; 75(3):486. PubMed ID: 36209513
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of botulinum toxin in treating scleroderma-associated raynaud's phenomenon: a systematic review and meta-analysis.
    Elrosasy A; Abo Zeid M; Cadri S; Fahmy BM; Elzeftawy MA; Mohammed F; Ramadan A
    Arch Dermatol Res; 2024 Apr; 316(5):122. PubMed ID: 38630277
    [No Abstract]   [Full Text] [Related]  

  • 3. Interventions for morphea.
    Albuquerque JV; Andriolo BN; Vasconcellos MR; Civile VT; Lyddiatt A; Trevisani VF
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD005027. PubMed ID: 31309547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review.
    García de la Peña Lefebvre P; Nishishinya MB; Pereda CA; Loza E; Sifuentes Giraldo WA; Román Ivorra JA; Carreira P; Rúa-Figueroa I; Pego-Reigosa JM; Muñoz-Fernández S
    Rheumatol Int; 2015 Sep; 35(9):1447-59. PubMed ID: 25824427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclofenil as a possible cause of non-arteritic anterior ischaemic optic neuropathy.
    Clarke B; Sykakis E; Parmar DN
    BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23264159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Treatment Options in Raynaud's Phenomenon.
    Generini S; Del Rosso A; Pignone A; Matucci Cerinic M
    Curr Treat Options Cardiovasc Med; 2003 Apr; 5(2):147-161. PubMed ID: 12686012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000955. PubMed ID: 10796397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000954. PubMed ID: 10796396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000956. PubMed ID: 10796398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The revised CONSORT statement for reporting randomized trials: explanation and elaboration.
    Altman DG; Schulz KF; Moher D; Egger M; Davidoff F; Elbourne D; Gøtzsche PC; Lang T;
    Ann Intern Med; 2001 Apr; 134(8):663-94. PubMed ID: 11304107
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.